

Proteinuria Lowered With Telmisartan

BY PATRICE WENDLING
Chicago Bureau

CHICAGO — Telmisartan provides greater reduction in proteinuria than losartan does after 1 year of treatment in patients with hypertension and diabetic nephropathy, Dr. George Bakris said at the annual meeting of the American Society of Hypertension.

This difference can't be attributed to differences in BP control, because BP reductions were comparable in patients taking either angiotensin II receptor blocker (ARB), Dr. Bakris, who is lead investigator of the AMADEO study, said in a press briefing.

After stopping the drugs for 2 months, as per protocol, about twice as many patients on telmisartan were reported to have experienced a slightly greater antiproteinuric effect than did those on losartan. This is important to clinicians, because it suggests that telmisartan has done something independent of controlling BP to change the natural history or biology of the disease. "The differences between these ARBs in terms of receptor binding, lipophilicity, and duration of action may be responsible for the differences in the effects that you see," said Dr. Bakris, director of the hypertension unit at the University of Chicago.

"These data suggest that at similar levels of blood pressure control, the longer-acting, higher-binding telmisartan may confer relatively greater protection against the development of end-stage renal disease, although that hypothesis needs to be tested prospectively," he said.

Dr. Bakris and associates randomized 860 patients with type 2 diabetes mellitus, hypertension (defined as BP > 130/80 mm Hg), and overt nephropathy to either telmisartan 40 mg or losartan 50 mg for 2 weeks, and then titrated to 80 mg and 100 mg, respectively. If blood pressure was not controlled, concomitant antihypertensives were allowed, except ARBs, ACE inhibitors, and direct vasodilators.

At admission, the average BP was 143/80 mm Hg in both groups; the mean urinary protein to creatinine ratio was 1,971 mg/gCr in the telmisartan group vs. 2,010.5 mg/gCr in the losartan group; and the mean serum creatinine level was 1.54 mg/dL in the telmisartan group vs. 1.55 mg/dL in the losartan group. In all, 827 patients were available for analysis.

After 1 year of treatment, the mean change in the morning spot urinary protein to creatinine ratio—the study's primary end point—was 0.71 for telmisartan and 0.80 for losartan. This translated to a 29% reduction from baseline for telmisartan and a 20% reduction for losartan.

BP reductions were not significant between groups (−4.8/−3.2 mm Hg vs. −2.7/−2.9 mm Hg, respectively).

Adverse events were not different between groups, said Dr. Bakris, who disclosed that he is a consultant and speaker for, and has received research support from, the study sponsor Boehringer Ingelheim. ■

ADVANCE Supports Lower Goals

Diabetic Patients from page 1

instead of 140 mm Hg, commented Dr. Sidney C. Smith Jr., director of the Center for Cardiovascular Science and Medicine at the University of North Carolina at Chapel Hill.

"The current target is 130/80 mm Hg, but we don't have good evidence supporting the systolic target. That's why this trial is important. This is further, confirmatory evidence that reducing blood pressure is important. But we need more data because we're still not at the target

level," said Dr. Smith, who is also vice chairman of the task force that produces treatment guidelines for the American College of Cardiology and the American Heart Association.

The new findings "strengthen the argument" in favor of a blood pressure target of 130 mm Hg for patients with diabetes, agreed Dr. Raymond J. Gibbons, professor of medicine at the Mayo Clinic in Rochester, Minn. He voiced hope that a stronger evidence base will better

motivate diabetic patients and their physicians to follow the JNC 7 BP guidelines.

The ADVANCE trial was run at 215 centers in 20 countries, sponsored in part by Servier, which markets a formulation of perindopril and indapamide (Preterax). A formulation that combines both of these drugs has not been approved by the Food and Drug Administration. The trial included another randomization that is testing the value of glycemic control with the drug gliclazide (Diamicron), but that analysis is not completed.

The study enrolled patients with type 2 diabetes who were at least 55 years old and had at least one other cardiovascular

High expectations
for lowering
very high triglycerides (≥500 mg/dL)

Important Safety Information:

1. LOVAZA is contraindicated in patients who exhibit hypersensitivity to any component of this medication.
2. Before instituting LOVAZA therapy, it should be confirmed that TG levels are consistently abnormal.
3. LOVAZA should be used with caution in patients with known sensitivity or allergy to fish.
4. The patient's TG, LDL-C and ALT levels should be monitored periodically during LOVAZA therapy. In some patients, LOVAZA increased LDL-C. LOVAZA therapy should be withdrawn in patients who do not have an adequate response after 2 months of treatment.
5. Some studies with omega-3-acids demonstrated prolongation of bleeding time, which did not exceed normal limits and did not produce clinically significant bleeding episodes. Patients receiving treatment with both LOVAZA and anticoagulants should be monitored periodically.
6. There are no adequate and well-controlled studies in pregnant women. Use LOVAZA during pregnancy only if the potential benefit justifies the potential risk to the fetus; and use with caution when administering LOVAZA to breastfeeding women.
7. LOVAZA was well-tolerated in controlled studies. The most common adverse events reported were: eructation, infection, flu syndrome, dyspepsia, rash, taste perversion, and back pain.
8. Please see full prescribing information.

References: 1. Lovaza Prescribing Information. Liberty Corner, NJ: Reliant Pharmaceuticals, Inc; 2007. 2. Data on file, Reliant Pharmaceuticals, Inc. 3. Ginsberg HN. Insulin resistance and cardiovascular disease. *J Clin Invest*. 2000;106:453-458. 4. Stalenhoef AFH, de Graaf JD, Wittekoek ME, Bredie SJH, Demacker PNM, Kastelein JJP. The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia. *Atherosclerosis*. 2000;153:129-138. 5. Garg R, Vasamreddy CR, Blumenthal RS. Non-high-density lipoprotein cholesterol: why lower is better. *Prev Cardiol*. 2005;8:173-177.



Reliant Pharmaceuticals, Inc.
Liberty Corner, NJ 07938

© 2007 Reliant Pharmaceuticals, Inc.

RLOV-C1005

August 2007